Home » Newsletters » BioWorld Science

BioWorld Science

June 22, 2011

View Archived Issues

Phase I data presented on MLN-9708 in multiple myeloma

Plerixafor is beneficial in patients with myelokathexis

PNB-01 is superior to citalopram in phase II trial in major depressive disorder

New inhibitors claimed of mitochondrial cytochrome P450 11B1 and 11B2

Novartis researchers synthesize new neprilysin inhibitors

Palatin Technologies discloses novel melanocortin MC1 receptor agonists

New NADPH oxidase 1, dual oxidase 2 and NADPH oxidase 3 inhibitors claimed

AstraZeneca claims new antagonists of P2X3 receptor and/or P2X2/3 heterodimer

Merck & Co. patents new GPR119 receptor agonists

MK-0916 reduces HbA1c and body weight in phase II trial in diabetes/metabolic syndrome

IBC Generium licenses rights in Russia to Affitech AT-001 antibody

FDA approves new tamper-resistant immediate-release oxycodone product Oxecta

EMA committee accepts for review PROLOR's PIP for long-acting human growth hormone

Pfizer discloses phase I data on PF-03084014 and PF-04554878 in solid tumors

MAb hu3S193 stabilizes disease in phase II trial in ovarian, peritoneal and fallopian tube cancer

Lead compound selected in Concert Pharmaceuticals/GSK HIV-PI collaboration

FDA removes clinical hold on SNS01-T IND in multiple myeloma

Concert Pharmaceuticals advances new drug candidates in kidney disease and spasticity

AVI BioPharma starts phase I trial of flu therapy AVI-7100

Cebix advances C peptide replacement therapy for chronic complications of diabetes

Topline phase III data show Lyrica efficaciously reduces neuropathic pain after spinal cord injury

Bristol-Myers Squibb to make milestone payment to Alder Biopharmaceuticals

Once-weekly exenatide approved in E.U. for type 2 diabetes

Jubilant and Endo Pharmaceuticals achieve third milestone in joint oncology program

Phase III LCP-Tacro trial in stable kidney transplant recipients meets primary endpoints

Lipid Therapeutics' phase IIb trial of LT-02 in ulcerative colitis meets primary endpoint

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...